Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Change in Acquisitions & Divestments (2016 - 2023)

Seres Therapeutics' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $11.8 million for Q2 2023.

  • For Q2 2023, Change in Acquisitions & Divestments fell 64.97% year-over-year to $11.8 million; the TTM value through Mar 2024 reached $11.8 million, down 89.08%, while the annual FY2023 figure was $23.0 million, 83.64% down from the prior year.
  • Change in Acquisitions & Divestments for Q2 2023 was $11.8 million at Seres Therapeutics, up from $11.2 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $54.8 million in Q2 2021 and bottomed at $2.5 million in Q3 2020.
  • The 5-year median for Change in Acquisitions & Divestments is $22.4 million (2020), against an average of $27.3 million.
  • The largest annual shift saw Change in Acquisitions & Divestments skyrocketed 1653.98% in 2021 before it tumbled 74.52% in 2023.
  • A 5-year view of Change in Acquisitions & Divestments shows it stood at $16.9 million in 2019, then increased by 1.68% to $17.2 million in 2020, then soared by 154.03% to $43.6 million in 2021, then crashed by 50.81% to $21.5 million in 2022, then crashed by 45.27% to $11.8 million in 2023.
  • Per Business Quant, the three most recent readings for MCRB's Change in Acquisitions & Divestments are $11.8 million (Q2 2023), $11.2 million (Q1 2023), and $21.5 million (Q4 2022).